- Overlapping ADAMTS13 peptide binding profiles of DRB1∗08:03 and DRB1∗11:01 suggest a common etiology of immune-mediated thrombotic thrombocytopenic purpura. [Journal Article]J Thromb Haemost. 2022 Dec 22 [Online ahead of print]JT
- CONCLUSIONS: Altogether, the findings of distinct HLA-DR association with iTTP across populations and the presentation of common peptides by DRB1∗08:03 and DRB1∗11:01 suggest that the same ADAMTS13-derived peptides might be presented and trigger the activation of autoreactive CD4+ T cells, leading to production of anti-ADAMTS13 autoantibodies by autoreactive B cells.
- Publisher Full Text (DOI)
- Hereditary thrombotic thrombocytopenic purpura acquired through liver transplantation: a case report. [Case Reports]Am J Transplant. 2022 Dec 30 [Online ahead of print]AJ
- A 62-year-old received orthotopic liver transplantation. Three weeks later, thrombotic microangiopathy developed. Testing revealed thrombotic thrombocytopenic purpura (TTP) characterized by low ADAMTS13 (A Disintegrin-like Metallopeptidase with ThromboSpondin type 1 motif 13) activity and no inhibitor of ADAMTS13 protein. Retrospective attainment of donor records revealed a TTP diagnosis, presuma…
- Publisher Full Text (DOI)
- "Development and internal validation of a clinical prediction model for the diagnosis of immune thrombocytopenia": reply. [Letter]J Thromb Haemost. 2023 Jan; 21(1):185.JT
- Publisher Full Text (DOI)
- "Development and internal validation of a clinical prediction model for the diagnosis of immune thrombocytopenia": comment from Beyan and Beyan. [Letter]J Thromb Haemost. 2023 Jan; 21(1):183-184.JT
- Publisher Full Text (DOI)
- Recurrent stroke in an African female with idiopathic thrombotic thrombocytopenic purpura: A case report. [Case Reports]
- We report on a young Ghanaian female who was diagnosed with thrombotic thrombocytopenic purpura (TTP) but had an ischemic stroke as the initial presentation. She was successfully treated with therapeutic plasma exchange. This case illustrates how TTP can masquerade as ischemic stroke and the application of PLASMIC score without ADAMTS-13 assay in risk prediction.
- PMC Free PDF
- Pseudo-thrombotic microangiopathy due to folate deficiency. [Case Reports]BMJ Case Rep. 2023 Jan 20; 16(1)BC
- Classically, deficiencies of vitamin B12 and folate are associated with megaloblastic anaemia. Additionally, vitamin B12 is able to cause a haemolytic anaemia in the form of pseudo-thrombotic microangiopathy (pseudo-TMA). Here, we present a case of a middle-aged woman with a history of Roux-en-Y gastric bypass who presented with dyspnoea and fatigue and was found to have thrombocytopenia and a no…
- Publisher Full Text (DOI)
- The phytoestrogenic potential of flavonoid glycosides from Selaginella moellendorffii via ERα-dependent signaling pathway. [Journal Article]J Ethnopharmacol. 2023 Jan 17 [Online ahead of print]JE
- CONCLUSIONS: ERα induction via mitogen-activated protein kinases (MAPK) and PI3K/Akt/mTOR pathways might be the possible mechanism underlying the phytoestrogen effect of SM, and the flavonoid glycosides might be the critical estrogenic constituents.
- Publisher Full Text (DOI)
- Investigation of the Active Compounds and Important Pathways of Huaiqihuang Granule for the Treatment of Immune Thrombocytopenia Using Network Pharmacology and Molecular Docking. [Journal Article]
- CONCLUSIONS: This study demonstrated that HQHG produced relief effects against ITP by regulating multitargets and multipathways with multicompounds. And the combined data provide novel insight of drug developing for ITP.
- PMC Free PDF
- Management of Helicobacter pylori infection. [Review]
- Helicobacter pylori infection exhibits a wide disease spectrum ranging from asymptomatic gastritis, peptic ulcer disease, to gastric cancer. H. pylori can induce dysbiosis of gastric microbiota in the pathway of carcinogenesis and successful eradication can restore gastric homeostasis. Diagnostic testing and treatment for H. pylori infection is recommended in patients with active or past history …
- PMC Free PDF
- How we treat primary immune thrombocytopenia in adults. [Review]
- Primary immune thrombocytopenia (ITP) is an immune-mediated bleeding disorder characterized by decreased platelet counts and an increased risk of bleeding. Multiple humoral and cellular immune abnormalities result in accelerated platelet destruction and suppressed platelet production in ITP. The diagnosis remains a clinical exclusion of other causes of thrombocytopenia. Treatment is not required …
- PMC Free PDF
- Efficacy and safety of biosimilar romiplostim in Indian patients with chronic immune thrombocytopenia: A multicentric retrospective study. [Journal Article]Indian J Pathol Microbiol. 2023 Jan-Mar; 66(1):96-100.IJ
- CONCLUSIONS: Biosimilar romiplostim was effective in achieving and maintaining platelet response without any new safety concerns in Indian adult patients with chronic ITP. The median effective dose of romiplostim required in our patients was lower as compared with the standard prescribed dose.
- Publisher Full Text (DOI)
- Efficacy and safety of cyclosporine-based regimens for primary immune thrombocytopenia: a systematic review and meta-analysis. [Meta-Analysis]
- CONCLUSIONS: Cyclosporine exhibited efficacy in the treatment of ITP without increasing the risk of ADRs.
- PMC Free PDF
- Thrombotic Microangiopathy in the Setting of Colorectal Cancer: A Therapeutic Challenge with a Bad Prognosis. [Case Reports]
- While most cases of thrombotic microangiopathic hemolytic anemias are idiopathic, some can occur in the setting of a malignancy. Differentiating both conditions is crucial to initiate the appropriate treatment. In this case report and literature review, we discuss the occurrence of a thrombotic microangiopathy in a 61-year-old male patient with a treatment-refractory metastatic colorectal cancer …
- PMC Free PDF
- Complement activation negatively affects the platelet response to thrombopoietin receptor agonists in patients with immune thrombocytopenia: a prospective cohort study. [Journal Article]Platelets. 2023 Dec; 34(1):2159019.P
- Increased platelet destruction is central in the pathogenesis of immune thrombocytopenia. However, impaired platelet production is also relevant and its significance underlies the rationale for treatment with thrombopoietin receptor agonists (TPO-RAs). Previous studies have associated enhanced complement activation with increased disease severity. Additionally, treatment refractoriness has been d…
- Publisher Full Text (DOI)
- Management of immune thrombotic thrombocytopenic purpura with caplacizumab: a Canadian, single-centre, real-world experience. [Journal Article]Platelets. 2023 Dec; 34(1):2157807.P
- When combined with therapeutic plasma exchange (TPE) and immunosuppression, upfront universal administration of caplacizumab was shown to be effective in the management of immune thrombotic thrombocytopenic purpura (iTTP). However, access to this drug remains challenging in many jurisdictions. We retrospectively review results of a single-institution experience with caplacizumab over a 3-year per…
- Publisher Full Text (DOI)
- Patient and Physician Perspectives in the Management of Immune Thrombocytopenia in Iran: Responses from the ITP World Impact Survey (I-WISh). [Journal Article]
- Data describing physicians' and patients' perspectives towards immune thrombocytopenia (ITP) management and impact of disease in Iran are limited. This ITP World Impact Survey was conducted between October 2019 and October 2020. Of the 114 patients included in the survey, 17 were aged ≤18 years. Forty-seven physicians, including 22 pediatric hematologists, participated in the survey. Fatigue and …
- PMC Free PDF
- Thrombotic thrombocytopenic purpura with neurological impairment: A Review. [Case Reports]
- The last 2 decades have witnessed considerable advances in our understanding of thrombotic thrombocytopenic purpura (TTP). However, there is still some ambiguity regarding the precise nature of this disease, especially with respect to nervous system involvement and the correct nomenclature. This article seeks to summarize the clinical manifestations of TTP and the associated diseases. We describe…
- PMC Free PDF
- Advances in management of pediatric chronic immune thrombocytopenia: a narrative review. [Journal Article]J Yeungnam Med Sci. 2023 Jan 09 [Online ahead of print]JY
- Immune thrombocytopenia (ITP) is a disease in which thrombocytopenia occurs because of immune-mediated platelet destruction and decreased platelet production. Although many pediatric patients with ITP experience spontaneous remission or reach remission within 12 months of first-line therapy, approximately 20% progress to chronic ITP. Patients who do not respond to first-line treatment or experien…
- Publisher Full Text (DOI)
- New strategies for the treatment of immune thrombocytopenia. [Interview]Clin Adv Hematol Oncol. 2022 03; 20(3):151-153.CA
- COVID-19 Vaccine-Associated Immune Thrombosis and Thrombocytopenia (VITT): Diagnostic Discrepancies and Global Implications. [Journal Article]Semin Thromb Hemost. 2023 Feb; 49(1):9-14.ST
- Vaccine-induced immune thrombotic thrombocytopenia (VITT) has been reported in association with the coronavirus disease 2019 preventative adenovirus vector-based vaccines ChAdOx1 nCoV-19 (Oxford/AstraZeneca) and Ad26.COV2.S (Janssen/Johnson & Johnson) in hundreds of recipients across the globe. VITT is characterized by thrombosis, typically at unusual sites, low fibrinogen, and elevated plasma D-…
- Publisher Full Text (DOI)
- What to expect when an ITP patient is expecting. [Editorial]
- Publisher Full Text (DOI)
- Pernicious Anemia and Vitamin B12 Deficiency Presenting As Pseudothrombotic Microangiopathy and Developing Secondary Thrombocytopenia After Treatment: A Case Report. [Case Reports]
- Pernicious anemia (PA) is an autoimmune disease secondary to chronic atrophic gastritis leading to vitamin B12 deficiency. Rarely, some patients may develop advanced hematological complications that mimic those of thrombotic thrombocytopenic purpura (TTP). Differentiating these conditions is crucial because they require different management. We present a case of a 68-year-old male who presented w…
- PMC Free PDF
- Immune-Mediated Adverse Drug Reactions (IM-ARDs) in the Form of Drug-Induced Immune Thrombocytopenia and Cutaneous Adverse Drug Reactions (CARD) Due to Clindamycin in an Human Immunodeficieny Virus (HIV) Patient. [Case Reports]Am J Case Rep. 2023 Jan 05; 24:e938358.AJ
- BACKGROUND Many drugs have been reported to cause immune-mediated adverse drug reactions (IM-ADRs) in human immunodeficiency virus (HIV) patients; the most common is cutaneous adverse drug reaction (CADR). Immune thrombocytopenia purpura (ITP) is frequent in HIV patients, and it can be caused HIV, opportunistic infections, or drugs. Although drugs can cause immune thrombocytopenia, termed drug-in…
- Publisher Full Text (DOI)
- Recombinant human thrombopoietin (rhTPO) of different dosing regimens for refractory/relapsed primary immune thrombocytopenia: a multicenter, randomized controlled trial and pharmacokinetics study. [Randomized Controlled Trial]Platelets. 2023 Dec; 34(1):2157806.P
- Recombinant human TPO (rhTPO) is effective for refractory/relapsed primary immune thrombocytopenia (ITP), but optimal dosing regimen remains elusive. In this multicenter, randomized, controlled trial, a total of 282 adult ITP patients (mean age 47.3 years; 82 men) with a platelet count ≤30 × 109/L or >30 × 109/L with active bleeding randomly received a once daily (QD) subcutaneous injection of 75…
- Publisher Full Text (DOI)
- Prolonged Thrombocytopenia in a Case of MIS-C in a Vaccinated Child. [Case Reports]
- Multisystem inflammatory syndrome in children (MIS-C) has been extensively described in patients following severe acute respiratory syndrome coronavirus 2 infection. There are now questions about what MIS-C may look like in vaccinated children. Multisystem inflammatory syndrome in children has many clinical and laboratory features in common with other inflammatory disorders including Kawasaki dis…
- PMC Free PDF
- Leukocytoclastic Vasculitis Masquerading as Chronic Idiopathic Thrombocytopenic Purpura. [Journal Article]
- CONCLUSIONS: Although most leukocytoclastic vasculitis cases are mild and resolve without intervention, many go undiagnosed due to biopsy delays. Health care professionals should determine and treat the underlying cause.
- PMC Free PDF
- Balancing the Qi in ITP. [Editorial]
- Publisher Full Text (DOI)
- Pediatric refractory immune thrombocytopenia: A systematic review. [Review]Pediatr Blood Cancer. 2023 Mar; 70(3):e30173.PB
- Pediatric immune thrombocytopenia (ITP) is an acquired disorder associated with autoimmune destruction and impairment of platelet production in children. Some children exhibit poor or transient response to ITP-directed treatments and are referred to as having refractory ITP (rITP). There is currently no consensus on the definition of rITP, nor evidence-based treatment guidelines for patients with…
- Publisher Full Text (DOI)
- Secondary immune-mediated thrombotic thrombocytopenic purpura in idiopathic inflammatory myopathy: a case-based review. [Review]
- Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal acquired thrombotic microangiopathy syndrome that frequently develops in the context of infectious diseases or systemic autoimmune conditions including connective tissue diseases. We report the case of a 42-year-old female suffering from severe iTTP associated with anti-Jo-1 positive antisynthetase syndrome, which w…
- PMC Free PDF
- Immune thrombocytopenic purpura secondary to COVID-19 vaccination: A systematic review. [Review]
- CONCLUSIONS: De novo ITP is a rare complication of COVID-19 vaccination, and corresponding reports belong to mRNA-based and adenovirus vector-based vaccines, in order of frequency. This frequency pattern may be related to the scale of administration of individual vaccines and their potency in inducing autoimmunity. The more the COVID-19 vaccine is potent to induce antigenic challenge, the shorter the lag time would be. Most patients had a benign course and responded to typical treatments of primary ITP.
- PMC Free PDF